Eton Financial Statements From 2010 to 2026

ETON Stock  USD 15.19  0.20  1.33%   
Eton Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Eton Pharmaceuticals' valuation are provided below:
Gross Profit
39.8 M
Profit Margin
(0.1)
Market Capitalization
402 M
Enterprise Value Revenue
5.6278
Revenue
70.3 M
We have found one hundred twenty available fundamental signals for Eton Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to verify Eton Pharmaceuticals' prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 26th of January 2026, Market Cap is likely to grow to about 82.9 M. Also, Enterprise Value is likely to grow to about 71.5 M

Eton Pharmaceuticals Total Revenue

47.11 Million

Check Eton Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eton Pharmaceuticals' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Depreciation And Amortization of 750.3 K or Interest Expense of 2.4 M, as well as many indicators such as Price To Sales Ratio of 9.66, Dividend Yield of 0.0214 or PTB Ratio of 6.65. Eton financial statements analysis is a perfect complement when working with Eton Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Eton Stock
Check out the analysis of Eton Pharmaceuticals Correlation against competitors.
To learn how to invest in Eton Stock, please use our How to Invest in Eton Pharmaceuticals guide.

Eton Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets91.9 M87.5 M30.5 M
Slightly volatile
Other Current Liabilities19.1 M18.1 M4.2 M
Slightly volatile
Total Current Liabilities24.1 M22.9 M6.4 M
Slightly volatile
Total Stockholder Equity18.6 M28.1 M15.7 M
Slightly volatile
Property Plant And Equipment Net178.7 K188.1 K306.5 K
Pretty Stable
Accounts PayableM4.8 M1.6 M
Slightly volatile
Cash14 M13.4 M15.3 M
Slightly volatile
Non Current Assets Total42.4 M40.4 M8.1 M
Slightly volatile
Non Currrent Assets Other10.3 K10.8 K28.7 K
Slightly volatile
Other Assets10.3 K10.8 K39.9 K
Very volatile
Cash And Short Term Investments14 M13.4 M15.3 M
Slightly volatile
Common Stock Total Equity20 K28.8 K15.1 K
Slightly volatile
Common Stock Shares Outstanding22.6 M29.8 M20 M
Slightly volatile
Liabilities And Stockholders Equity91.9 M87.5 M30.5 M
Slightly volatile
Non Current Liabilities Total38.3 M36.5 M7.9 M
Slightly volatile
Capital Surpluse82 M133.6 M55.8 M
Slightly volatile
Other Current Assets6.6 M6.3 M1.8 M
Slightly volatile
Other Stockholder Equity101.2 M152.1 M58.9 M
Slightly volatile
Total Liabilities62.4 M59.4 M14.2 M
Slightly volatile
Property Plant And Equipment Gross485.1 K589.5 K397.6 K
Slightly volatile
Total Current Assets26.4 M47.2 M21.1 M
Slightly volatile
Net Working Capital13.6 M19 M15.1 M
Slightly volatile
Common Stock23.2 K31.1 K15.6 K
Slightly volatile
Property Plant Equipment61.6 K64.8 K268.6 K
Very volatile
Capital Stock25.6 K31.1 K21.4 K
Slightly volatile
Short and Long Term Debt Total36.1 M34.4 M10.2 M
Slightly volatile
Net Receivables6.5 M6.2 MM
Slightly volatile
Long Term Debt TotalM6.2 MM
Slightly volatile
Capital Lease Obligations67.7 K123 K43 K
Slightly volatile
Non Current Liabilities Other2.2 M2.1 M512.2 K
Slightly volatile

Eton Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization750.3 K1.3 M448 K
Slightly volatile
Selling General Administrative14.4 M26.2 M10.5 M
Slightly volatile
Other Operating Expenses26.3 M47.8 M18.6 M
Slightly volatile
Research Development5.2 M2.9 M5.2 M
Pretty Stable
Cost Of Revenue18.8 M17.9 M4.3 M
Slightly volatile
Total Operating Expenses21.3 M29.9 M15.1 M
Slightly volatile
Interest Income244.8 K323.1 K219.4 K
Slightly volatile
Reconciled Depreciation855.5 K1.3 M477.7 K
Slightly volatile

Eton Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock214.6 K225.9 K11.6 M
Slightly volatile
Stock Based Compensation3.1 M3.6 M2.8 M
Slightly volatile
Other Cashflows From Financing Activities212 K223.2 K8.6 M
Slightly volatile
Depreciation750.3 K1.3 M448 K
Slightly volatile
Other Non Cash Items697.3 K1.1 MM
Slightly volatile
Capital Expenditures28.4 K29.9 K592.8 K
Slightly volatile
End Period Cash Flow14 M13.4 M15.3 M
Slightly volatile
Change To Netincome3.7 M4.9 M3.3 M
Slightly volatile
Begin Period Cash Flow19.7 M24.6 M16.2 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio9.6610.17338
Very volatile
Dividend Yield0.02140.0240.0262
Slightly volatile
PTB Ratio6.6512.718.7516
Very volatile
Days Sales Outstanding54.857.68151
Slightly volatile
Book Value Per Share1.221.080.9449
Pretty Stable
Stock Based Compensation To Revenue0.08860.09335.0855
Very volatile
Capex To Depreciation0.02480.02612.793
Slightly volatile
PB Ratio6.6512.718.7516
Very volatile
EV To Sales10.0810.61312
Very volatile
Inventory Turnover0.880.922.5768
Slightly volatile
Days Of Inventory On Hand437410352
Very volatile
Payables Turnover3.543.371.3489
Slightly volatile
Sales General And Administrative To Revenue0.640.6724.1151
Very volatile
Research And Ddevelopement To Revenue0.09120.09628.4106
Very volatile
Capex To Revenue7.0E-48.0E-41.2258
Slightly volatile
Cash Per Share1.280.660.9681
Very volatile
Days Payables Outstanding1071127.9 K
Slightly volatile
Intangibles To Total Assets0.430.410.1303
Slightly volatile
Current Ratio2.252.3610.496
Slightly volatile
Receivables Turnover4.656.553.7827
Slightly volatile
Shareholders Equity Per Share1.221.080.9449
Pretty Stable
Debt To Equity1.161.10.5582
Slightly volatile
Capex Per Share9.0E-49.0E-40.028
Pretty Stable
Revenue Per Share1.421.360.4573
Slightly volatile
Interest Debt Per Share1.161.110.4228
Slightly volatile
Debt To Assets0.220.350.2694
Pretty Stable
Operating Cycle592468510
Very volatile
Price Book Value Ratio6.6512.718.7516
Very volatile
Days Of Payables Outstanding1071127.9 K
Slightly volatile
Ebt Per Ebit0.871.321.0525
Pretty Stable
Company Equity Multiplier1.422.81.5353
Slightly volatile
Long Term Debt To Capitalization0.260.490.3342
Slightly volatile
Total Debt To Capitalization0.270.50.3246
Slightly volatile
Debt Equity Ratio1.161.10.5582
Slightly volatile
Quick Ratio1.411.4910.3044
Slightly volatile
Net Income Per E B T1.31.151.3219
Slightly volatile
Cash Ratio0.820.869.8306
Slightly volatile
Days Of Inventory Outstanding437410352
Very volatile
Days Of Sales Outstanding54.857.68151
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.120.97321.0333
Very volatile
Price To Book Ratio6.6512.718.7516
Very volatile
Fixed Asset Turnover17616854.7621
Slightly volatile
Debt Ratio0.220.350.2694
Pretty Stable
Price Sales Ratio9.6610.17338
Very volatile
Asset Turnover0.430.460.271
Slightly volatile
Price Fair Value6.6512.718.7516
Very volatile

Eton Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap82.9 M63.8 M96.5 M
Slightly volatile
Enterprise Value71.5 M55 M84 M
Slightly volatile

Eton Fundamental Market Drivers

Forward Price Earnings12.8041
Cash And Short Term Investments14.9 M

Eton Upcoming Events

21st of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Eton Pharmaceuticals Financial Statements

Eton Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Eton Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-119.7 K-125.7 K
Total Revenue44.9 M47.1 M
Cost Of Revenue17.9 M18.8 M
Stock Based Compensation To Revenue 0.09  0.09 
Sales General And Administrative To Revenue 0.67  0.64 
Research And Ddevelopement To Revenue 0.10  0.09 
Revenue Per Share 1.36  1.42 
Ebit Per Revenue(0.06)(0.06)

Pair Trading with Eton Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eton Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eton Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Eton Stock

  0.83JAGX Jaguar Animal HealthPairCorr

Moving against Eton Stock

  0.87JNJ Johnson JohnsonPairCorr
  0.82MRK Merck CompanyPairCorr
  0.75PFE Pfizer Inc Sell-off TrendPairCorr
  0.72PPERY Bank Mandiri PerseroPairCorr
  0.71PPERF Bank Mandiri PerseroPairCorr
The ability to find closely correlated positions to Eton Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eton Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eton Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eton Pharmaceuticals to buy it.
The correlation of Eton Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eton Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eton Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eton Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Eton Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eton Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eton Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eton Pharmaceuticals Stock:
Check out the analysis of Eton Pharmaceuticals Correlation against competitors.
To learn how to invest in Eton Stock, please use our How to Invest in Eton Pharmaceuticals guide.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eton Pharmaceuticals. If investors know Eton will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eton Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.13)
Earnings Share
(0.26)
Revenue Per Share
2.633
Quarterly Revenue Growth
1.175
Return On Assets
0.0126
The market value of Eton Pharmaceuticals is measured differently than its book value, which is the value of Eton that is recorded on the company's balance sheet. Investors also form their own opinion of Eton Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eton Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eton Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eton Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eton Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eton Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eton Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.